{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = [2-(Pyridine-4-carbonyl)hydrazinyl]methanesulfonic acid
| image = Methaniazide.svg
| width = 

<!--Clinical data-->
| tradename = Erbazid, Neoiscotin, Neo-Iscotin, Nesticide, Neotizide, Neo-Tizide
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 13447-95-5
| CAS_supplemental = <br />3804-89-5 ([[sodium]])
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3769
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 3637
| UNII = GN8S7ZES0F
| KEGG = D08198
| ChEBI = 134943
| ChEMBL = 2105190

<!--Chemical data-->
| C=7 | H=9 | N=3 | O=4 | S=1
| SMILES = C1=CN=CC=C1C(=O)NNCS(=O)(=O)O
| StdInChI_Ref = 
| StdInChI = 1S/C7H9N3O4S/c11-7(6-1-3-8-4-2-6)10-9-5-15(12,13)14/h1-4,9H,5H2,(H,10,11)(H,12,13,14)
| StdInChIKey_Ref = 
| StdInChIKey = GQZQCROBCYNTMU-UHFFFAOYSA-N
| synonyms = Metaniazide; Neotizide; Isoniazid methanesulfonate; Isoniazid methanosulfonate; Isoniazid mesylate; Isonicotinic acid hydrazide methanesulfonate
}}

'''Methaniazide''', brand name '''Neotizide''' among others, is an [[antibiotic]] which is used in the treatment of [[tuberculosis]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA709|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=709–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA177|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=177–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/methaniazide.html</ref> It is the [[mesylate]] (methanesulfonate) [[ester]] of isoniazid, which is also an antituberculosis drug but has comparatively been far more widely known and used.<ref name="Elks2014" /> Isoniazid is a [[prodrug]] of [[isonicotinic acid]], and [[acetylisoniazid]], a [[metabolite]] of isoniazid, is a [[metabolic intermediate]] through which most of the isonicotinic acid is formed.<ref name="TestaMayer2003">{{cite book|author1=Bernard Testa|author2=Joachim M. Mayer|title=Hydrolysis in Drug and Prodrug Metabolism|url=https://books.google.com/books?id=U-PDqHikphYC&pg=PA149|date=August 2003|publisher=John Wiley & Sons|isbn=978-3-906390-25-3|pages=149–}}</ref> Methaniazide features its mesylate ester at the same position as that of the acetyl ester in acetylisoniazid, and so methaniazide probably acts as a prodrug of isonicotinic acid similarly to isoniazid and acetylisoniazid. Methaniazide is used as the [[sodium]] [[salt (chemistry)|salt]].<ref name="Elks2014" />

[[Neothetazone]] is an antibiotic [[combination drug|combination]] of methaniazide ('''neo'''tizide) and [[thioacetazone|'''th'''ioac'''etazone''']] which is or was previously used in the treatment of tuberculosis.<ref name="SAMJ1970">{{cite book|title=SAMJ|url=https://books.google.com/books?id=sDRRAQAAIAAJ|year=1970|publisher=Medical Association of South Africa|pages=449–450|quote=Diffuse hypertrophy of the breasts seems to have been associated in this patient with treatment with Neothetazone, which consists of neotizide and thiacetazone, and which is very commonly used in the treatment of tuberculosis.}}</ref> It has been associated with a case report of [[gigantomastia]].<ref name="SAMJ1970" /><ref name="pmid12187348">{{cite journal | vauthors = Sakai Y, Wakamatsu S, Ono K, Kumagai N | title = Gigantomastia induced by bucillamine | journal = Annals of Plastic Surgery | volume = 49 | issue = 2 | pages = 193–5 | year = 2002 | pmid = 12187348 | doi = 10.1097/00000637-200208000-00013| url = | quote = Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone. [...] It is rare for breast hypertrophy to be induced by drugs. In particular, gigantomastia has been reported to be induced by only two drugs: D-penicillamine and the antibiotic neothetazone. [...] In 1970, drug-induced gigantomastia was reported for the first time by Scott.4 It was induced by the antibiotic Neothetazone.}}</ref><ref name="pmid18054304">{{cite journal | vauthors = Dancey A, Khan M, Dawson J, Peart F | title = Gigantomastia--a classification and review of the literature | journal = Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS | volume = 61 | issue = 5 | pages = 493–502 | year = 2008 | pmid = 18054304 | doi = 10.1016/j.bjps.2007.10.041 | url = }}</ref> Similarly, there have been a variety of case reports in the literature of [[gynecomastia]] associated with isoniazid treatment.<ref name="pmid22628943">{{cite journal | vauthors = Khan A, Agarwal R | title = Isoniazid related gynecomastia: Description of a case and systematic review of literature | journal = Lung India | volume = 29 | issue = 2 | pages = 189–91 | year = 2012 | pmid = 22628943 | pmc = 3354502 | doi = 10.4103/0970-2113.95343 | url = }}</ref>

==References==
{{Reflist|2}}


{{Antimycobacterials}}
{{Cell wall disruptive antibiotics}}
{{Hydrazines}}

[[Category:Anti-tuberculosis drugs]]
[[Category:Hydrazides]]
[[Category:Isonicotinamides]]
[[Category:Prodrugs]]
[[Category:Sulfonic acids]]


{{antibiotic-stub}}